EpiCept Reports Second Quarter 2013 Operating and Financial Results

barbara.lempert

Special August 6 Stockholder Meeting to Approve Final Conditions to Merger with Immune Pharmaceuticals
TARRYTOWN, N.Y., Aug. 1, /PRNewswire/ — Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) today announced and for the three and six months ended June 30, , and provided an update on the Company’s upcoming merger with Immune Pharmaceuticals, Ltd. (Immune).
Robert Cook, Interim President and CEO of EpiCept, commented, “Our excitement about the merger between EpiCept and Immune is growing as we get closer to the stockholder vote on August 6 and to the closing of the merger transaction shortly after obtaining stockholder approval. We believe the combination of our companies will benefit both sets of shareholders and will in particular provide EpiCept’s stockholders with a great opportunity to participate in the antibody therapeutics sector, one of the most dynamic in the biotech industry. We look forward to our transition into a new company, Immune Pharmaceuticals, Inc, focused on these cutting-edge products.”
Mr. Cook added, “We are very pleased with the results of the vote to date with more than 93% of the votes cast so far in favor of the proposals.  We fully anticipate that our Special Meeting of Stockholders on August 6 will result in our meeting the final conditions to the closing of this important transaction.”
Merger Update
In November 2012, following the approval of the companies’ respective boards of directors, EpiCept signed a merger agreement with Immune Pharmaceuticals Ltd., a private company based in Herzliya-Pituach, Israel and New York, NY. The terms of the merger agreement provide that, upon the closing of the transaction, EpiCept will issue shares of its common stock to Immune shareholders in exchange for all outstanding shares of Immune and issue options and warrants to purchase shares of its common stock in exchange for certain options and warrants to…Read more

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS